Press Releases :: CytoDyn Inc. (CYDY)

For the latest results and updates on our Phase 2 CRC trial and more, here’s a direct link to our recent presentations

Learn More

CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Mar 05, 2026 8:30am EST

CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference

Feb 20, 2026 8:30am EST

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

Jan 27, 2026 8:30am EST

December 2025 Letter to Shareholders

Dec 16, 2025 8:30am EST

CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Dec 08, 2025 8:30am EST

CytoDyn Announces Resolution of Class Action Lawsuit

Dec 01, 2025 8:30am EST

CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium

Nov 24, 2025 8:30am EST

CytoDyn Secures $30 Million Commitment from Yorkville Advisors

Nov 03, 2025 8:30am EST

CytoDyn to Present at the LD Micro Main Event XIX Investor Conference

Oct 09, 2025 8:30am EDT

September 2025 Letter to Shareholders

Sep 30, 2025 8:30am EDT

1
2
3
4
5
6
7
8